Roche (OTCMKTS:RHHBY) Stock Rating Upgraded by Hsbc Global Res

Key Points

• Roche's stock rating was upgraded from "hold" to "strong-buy" by HSBC Global Research, with a price target of $50.00.
• The company's stock currently has a consensus rating of "Buy", with three analysts rating it as Strong Buy.
• Shares of Roche opened at $44.70, with a 12-month price range between $34.10 and $45.08.

Roche (OTCMKTS:RHHBY - Get Free Report) was upgraded by equities research analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating in a research note issued on Thursday,Zacks.com reports.

Separately, HSBC raised shares of Roche from a "hold" rating to a "buy" rating and set a $50.00 price objective on the stock in a research report on Thursday. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $50.00.

Roche Stock Down 0.3%

Shares of RHHBY opened at $44.70 on Thursday. Roche has a twelve month low of $34.10 and a twelve month high of $45.08. The firm's 50 day moving average price is $40.68 and its two-hundred day moving average price is $40.26.

Institutional Investors Weigh In On Roche

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RHHBY. GAMMA Investing LLC lifted its position in Roche by 17.4% during the 3rd quarter. GAMMA Investing LLC now owns 18,899 shares of the company's stock worth $790,000 after buying an additional 2,798 shares in the last quarter. Knuff & Co LLC acquired a new stake in shares of Roche in the second quarter valued at about $255,000. North Star Asset Management Inc. raised its holdings in Roche by 52.0% during the second quarter. North Star Asset Management Inc. now owns 26,305 shares of the company's stock worth $1,072,000 after acquiring an additional 9,000 shares in the last quarter. Enterprise Financial Services Corp bought a new position in Roche in the second quarter valued at approximately $208,000. Finally, Rhumbline Advisers increased its position in shares of Roche by 1.1% during the 2nd quarter. Rhumbline Advisers now owns 108,480 shares of the company's stock worth $4,422,000 after purchasing an additional 1,228 shares during the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.